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Abstract  
 Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a 
potentially life threatening disease endemic to Latin America that has re-emerged as a 
global public health issue due to globalization. While this disease has been known of for 
hundreds of years, detection methods are still not straight forward; especially for the 
chronic phase of the disease. There is no golden standard for diagnosis and current 
detection methods rely on indirect tests such as serology; which has proven to be a 
suboptimal approach due to immunological and geographical variability.  
Here, we report on a direct form of noninvasive diagnosis, focused on the detection 
of T. cruzi-derived cell-free DNA in the urine of Chagas Disease patients. For this study, 
samples were collected, stored, and processed using a filtration/extraction method. DNA 
was analyzed through conventional and nested PCR protocols, with three different primer 
sets targeting T. cruzi k-DNA or Sat-DNA repeat sections. The resulting positive PCR 
samples were confirmed through sequencing and compared against serological results. We 
found that T. cruzi DNA is indeed present in the urine of Chagas disease patients. 
While further studies with a larger population are needed for improved primer 
development, the detection of T. cruzi DNA in urine has the potential to provide a novel 
non-invasive diagnostic method for Chagas disease that can be employed to improve 
chronic phase detection, treatment-monitoring, early detection in congenital disease cases 
and the management of immunosuppressed patient.  
Primary reader: Dr. Alan L. Scott 
Secondary reader: Dr. Clive J. Shiff 
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I. Introduction 
 
Chagas disease, a neglected tropical infection endemic to Latin America, has re-
emerged as a global public health issue due to globalization and migration movements1,2; 
with approximately 8 million people infected worldwide and at least 100 million at risk of 
infection. This complex disease, caused by the protozoan parasite Trypanosoma cruzi (T. 
cruzi), consists of an acute and chronic phase that can cause heart and gastrointestinal 
issues depending on disease progression. While Chagas disease was formally described by 
Carlos Chagas 110 year ago (in 1909), there is still no single test for definitive diagnosis 
of infection with this protozoan pathogen.  Detection of infection is complex, and the 
method used depends on the phase of the disease. For acute stages, identification of 
parasites in a blood smear is sufficient for definitive diagnosis.  In cases of chronic disease 
when the parasite resides inside cells of somatic tissues, two serological analyses are 
recommended for a confirmatory diagnosis. However, serological tests have complications 
and are known to have regional variations in sensitivity3,4 making diagnosis suboptimal 
and treatment-monitoring difficult5. To add to the diagnostic complications, the acute phase 
is often asymptomatic and detection in the chronic phase is hampered due to the parasite’s 
concealed presence within host cells.  These factors result in a serious under-diagnosis of 
T. cruzi infections in endemic and non-endemic areas.  These diagnostic issues are also of 
importance in nonendemic areas, since health systems typically lack personnel with 
experience in recognizing and treating Chagas disease patients1,6, especially in patients 
who present with reactivation or chronic disease.  
It is also important to note that no specific treatments are currently available. 
Benznidazole and nifurtimox, which are the only current chemotherapy options, have 
 
2 
 
severe adverse effects and are not recommended for patients >50 years of age. In addition, 
these compounds are only effective against extracellular trypanosomes and not against 
intracellular amastigotes.  As a result, cases of re-emergence of disease can occur. Also, 
chronic disease effects (such as cardiomyopathy, megacolon, and megaesophagus) require 
surgery or organ transplant, making early detection and speedy treatment of Chagas disease 
key for effective remedy.  
In order to contend with these emerging issues, new strategies for diagnosis are 
needed. Different PCR strategies have emerged for identification of T. cruzi. Most focusing 
in DNA detection from blood samples, with primers targeting repetitive conserved DNA 
fragments found in either T. cruzi kinetoplast-DNA (k-DNA) or Satellite-DNA (Sat-
DNA)7–10. So far, these new strategies are only used for serologically indeterminate 
samples, and screening tests with better sensitivities are being developed. Even then, these 
techniques work better for the acute phase, when there is a greater number of parasites in 
blood. In cases of chronic disease, the parasite is found in tissues and parasitemia levels 
are low, causing further complications for serological diagnosis. 
This is why we have chosen to focus on an alternative diagnosis method that detects 
cell-free DNA in urine (also known as transrenal DNA or Tr-DNA) using PCR techniques 
targeting either T. cruzi k-DNA or Sat-DNA repeats. The detection of T. cruzi DNA in 
urine has the potential to provide a novel non-invasive diagnostic method for Chagas 
disease. PCR assays have previously demonstrated positive results days to weeks before 
circulating trypomastigotes are visible by microscopy of peripheral blood11. This may help 
improve chronic phase detection, treatment-monitoring, early detection in newborns from 
infected mothers (congenital disease) and manage immunosuppressed patients. The 
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utilization of filter paper for urine samples further facilitates sample collection, storage and 
transportation.  
We hypothesis that cell-free T. cruzi DNA is accessible from the urine of patients 
as Tr-DNA and the PCR-based detection of T. cruzi Tr-DNA is a sensitive and specific 
measure of both the acute and chronic phases of Chagas disease.  
In the following Chapters, I will describe Chagas Disease, going in depth into the 
parasite, its morphology and life cycle, what is known about its genetic makeup, the current 
worldwide view of Chagas disease and issues concerning its diagnosis.  
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Background 
 
The Parasite 
T. cruzi belongs to the genus Trypanosoma, a group of unicellular flagellate 
parasitic protozoa of the order Kinetoplastida.  Trypanosomes are parasites that require 
both an insect vector and a vertebrate host in order to complete their natural life cycle. 
What differentiates T. cruzi from other members of the Trypanosoma genus is that they 
require an intracellular developmental stage in their vertebrate host and are mainly 
transmitted by the blood-feeding Triatomine bugs (commonly known as “kissing bugs”, or 
“chinche”).  
 
Morphology & Lifecycle 
T. cruzi changes its morphology throughout its different life cycle stages, going 
through three developmental forms: epimastigote, trypomastigote, and amastigote. A 
diagram of the life cycle by Pérez-Molina et al.5 can be seen in Figure 1. The cycle starts 
when a reduviid vector acquires infection by ingesting circulating trypomastigotes from an 
infected host during a bloodmeal.  Inside the vector, the trypomastigotes develop into 
epimastigotes, which replicate by binary fission in the insect midgut and differentiate into 
infective metacyclic trypomastigotes in the hindgut. The parasites are deposited within the 
vector’s feces onto their mammalian host when the reduviid bug takes a blood meal. 
Infection is initiated when metacyclic trypomastigotes enter the bite wound site when the 
feces are rubbed or scratched onto the wound, or through mucosal membranes such as the 
eyes. Once inside the host, the metacyclic trypomastigotes penetrate any nucleated 
cell (with preference for muscle and epithelial cells, neurons, and reticuloendothelial cells) 
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and transform into amastigotes, again multiplying by binary fission and transforming into 
trypomastigotes. Once transformed they burst out of the cell and enter the bloodstream, 
where they can either penetrate another cell or be ingested by the vector12. 
Figure 1) T. cruzi life cycle. Source: Chagas disease. Molina J, et al. The Lancet 2018; 391:1700115-82.  
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The three forms of the parasite can be distinguished by the positions of their nucleus 
and kinetoplast (a network of circular DNAs representing many copies of the mitochondrial 
genome; see below) [Figure 2]. Trypomastigotes, found in the blood stream of mammalian 
hosts, average 20 μm in length and can take on either a long and slender morphology or a 
short and stumpy morphology13. These are the only forms of the parasite that are detected 
in Giemsa stained blood films, were they are generally seen in a C or U/S shape [Figure 
2]. This form is distinguished by having a centrally positioned nucleus and a kinetoplast 
towards the posterior end, an undulating membrane and a flagellum running along the 
undulating membrane and extending from the body on the anterior end. The parasites also 
contain a flagellum that runs from the kinetoplast through the parasite’s body and extends 
beyond it. Epimastigotes, found in the insect vector gut, are similar to trypomastigotes in 
general morphology but this time the kinetoplast is located anterior to the nucleus. 
Amastigotes, in the other hand, are found within the mammalian host tissue and are 
generally round (~2-4 μm) with an almost nonexistent flagellum. 
 
Figure 2) T. cruzi Morphology. A. T. cruzi morphology simplified cartoon adapted from 
Sunter, K=Kinetoplast, N=Nucleolus, F=Flagella, UM= Undulating Membrane. B. 
Trypomastigote in a thin blood smear stained with Giemsa, CDC. C. Morphology 
adapted from Souza 1999. 
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Phylogenetic Relationship 
As mentioned above, T. cruzi belongs to the genus Trypanosoma, a genus that also 
encompasses other species that cause vector-borne diseases in humans; Trypanosoma 
brucei the etiological agent of Human African Trypanosomiasis (and another similar 
disease in livestock from related species); as well as Leishmania which causes different 
forms of leishmaniasis in humans. Figure 3 contains a cladogram representing their 
consensus phylogeny14 and was 
built based on MSP (Major Surface 
Proteases) gene family phylogeny 
rooted to Ichthyobodo necator. 
While the T. cruzi gene repertoire is 
broadly conserved in their 
chromosomal cores14, their sub-
telomeric regions demonstrated 
species-specific features; many of 
which encode cell surface proteins. 
While these regions help 
distinguish between the species, 
certain cell surface-associated 
protein families (such as δ-amastin expressed during the amastigote stage) are similar 
enough between Leishmania species and Trypanosoma cruzi15 to result in cross reactivity 
(false positives) during certain serological, and rapid, diagnostic tests14. 
 
Figure 3) Trypanosomatidae phylogeny cladogram (edited 
from/adapted from Jackson, 2014). Note that this cladogram 
was built based on MSP gene family phylogeny and rooted to 
Ichthyobodo necator. 
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Genome 
The T. cruzi genome was sequenced from a hybrid strain (CL Brener- TcVI) by the 
genome sequencing project16. However, its diversity and repetitive nature have made it 
difficult to completely assemble the linear sequence of its chromosomes. It is estimated 
that over 50% of the genome consists of repeated sequences17,18. Combined with its 
abundant level of diversity, the genome cannot be adequately defined by current genetic 
typing methods19. So far it has been found that T. cruzi is a diploid organism with 
homologous pairs of  aneuploid chromosomes that vary in number and size among strains 
(varying up to 1.57-fold between strains)16,19–22. The mean nuclear genome size has been 
found to be 125 Mb (for TcII, TcV and TcVI isolates) and 89.5 Mb (for TcI isolates)16. 
This difference in sizes is in part attributed to a difference in number of repeat sections of 
DNA - as reported by Souza et al. – providing an explanation for   the wide variation in 
genome size observed among eukaryotic species, which is more closely correlated with the 
amount of repetitive DNA than with the number of coding genes including 
retrotransposons and satellite DNA16.  
Satellite DNA (or Sat-DNA) is composed of very large arrays of tandemly repeated 
(a pattern of one or more nucleotides repeated directly adjacent to each other), non-coding 
DNA found in the centromeres. Sat-DNA was found to be 2.3 to 3.8 times more abundant 
in TcII, TcV and TcVI isolates than in TcI isolates16, confirming that repeats do contribute 
to the difference in size of their genomes. A section of the nuclear mini-satellite region 
designated TCZ is present in 120,000 copies in the parasite genome, it is a repeated 195 
bp sequence and represents 10 % of the parasites’ total DNA 23.  
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Aside from nuclear-DNA, T. cruzi also contains a mitochondrial genome, known 
as the kinetoplast, that is composed of a complex of concatenated circles and minicircles. 
The minicircles represent 95% of the total kinetoplast-DNA 
(or k-DNA) and the whole mitochondrial genome represents 
about 20% of the parasite’s total DNA23. K-DNA contains a 
high number of copies (10,000), and each minicircle is 
known to contain four regions of highly conserved DNA 
sequences (120 bp) between strains, and 4 regions of 
variable DNA (330 pb) [Figure 4]23,24. The total amount of 
DNA (nuclear plus kinetoplast) ranges between 0.12 to 0.33 pg per cell depending on the 
strain and clone16. Since both Sat-DNA and k-DNA are present in multiple copies they can 
be used to our advantage in order to make diagnostic tests more sensitive. The most widely 
used PCR assays used for diagnostic of blood samples target either the k-DNA, or Sat-
DNA repeat region23. 
  
 
Figure 4) Representation 
of k-DNA minicircle 4 
conserved (bold lines) and 
4 variable (thin sections) 
domains. 
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Population Genetic Diversity 
The wide genetic diversity of T. cruzi is currently classified into six genetic groups 
knowns as discrete typing units (DTUs), named TcI to TcVI, and a seventh unit called 
TcBat25,26. Several genetic molecular markers are used to classify the DTUs after their 
isolation in culture or directly from biological samples. The different DTUs present 
substantial genetic diversity with reports showing its effect on the parasite’s biological, 
medical, and epidemiological characteristics27.  
A study27 compiled a total of 
6,343 published works to identify the 
DTUs of T. cruzi strains and their current 
diversity represents their overall 
distribution in the Americas [Figure 5]. 
TcI is predominant in the overall sample 
(around 60%), in both sylvatic and 
domestic cycles27. However, it is known 
that various DTUs can coexist in the same 
vector and in a single host27,28, which 
could affect detection of overlapping 
DTU’s in a single host.  
  
Figure 5) T. cruzi overall DTU distribution in the 
Americas. Source: Breniere et al, PLOS 2016; 
Breniere 
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Epidemiology 
Epidemiology of Reduviid bug – 
In endemic regions, T. cruzi, is 
mainly transmitted by blood sucking 
Triatomine bugs, better known as “kissing 
bugs” (since they like to feed around the 
mouth of people). They are a subfamily 
from the Reduviidae, which is composed of 
mainly terrestrial ambush predators.  They are easily recognized by their sturdy body, 
narrow neck, and their large curved proboscis29, Figure 6. The parasite has a very broad 
range of insect hosts with more than 150 species of triatomines serving as an intermediate 
host.  In turn, these bugs can transmit T. cruzi to over 100 species of mammals (reservoir 
hosts; such as armadillos, pigs, dogs, and cats) that maintain a large range of possible 
zoonotic sources to infect humans (definitive host).   In the Americas, the range of the 
insects extends from the United states to Argentina and Chile with a total of 22 endemic 
countries30. 
Historically, the disease existed mainly in wild animals and rural areas.  The disease 
was spread to domestic animals and to humans due to urbanization and rural exodus that 
has resulted in a shift in infection to urban or peri-urban areas31.  
 
Prevalence in Latin America–  
Chagas disease has been a major public health problem in Latin American for many 
decades. Its area of endemicity includes countries such as Argentina, Brazil, Chile, El 
Salvador, Uruguay, and Mexico. Chagas disease is of main concern due to its 
Figure 6) Triatomine bug, CDC12. 
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incapacitating effects and cardiac issues. In these endemic regions, the main mode of 
transmission is vector-borne. In 2010 Argentina, Brazil and Mexico were found to have 
the highest estimated number of T. cruzi-infected people (1,505,235; 1,156,821; and 
876,458, respectively), Bolivia was found to have the highest estimated number of vectorial 
transmissions (8,087) followed by Mexico (6,135) and Colombia (5,274)5,32. 
 With a number of measures for Chagas disease control setup up in the 1990s – such 
as vector control, improved housing programs, better detection programs, compulsory 
blood bank testing, and blood transfusion safety improvements – the incidence of T. cruzi 
infections has been reduced by an estimated 70%5,33. Prevalence has also decreased to the 
point of interrupting transmission for Uruguay in 1997, for Chile in 1999, and for most of 
Brazil in 20005. The vector control program in Brazil has resulted in a documented savings 
in medical care and disabilities by US$17 for each dollar spent in prevention33. 
However, even with this progress, Chagas is still considered a threat. Since Chagas 
disease is not only vector-borne - it can also be transmitted through blood transfusions, 
organ transplantation, from mother to child (congenitally), or orally through contaminated 
food (only seen in the Amazon basin34. These and other issues, such as resistance to 
pyrethroid insecticides by the vector35, have hampered disease control initiatives and 
increased frequency of transmission. Also, in South America, heart failure (which presents 
high mortality) is one of the main causes of hospitalization. It was estimated that the 10-
year mortality rate for Chagas disease patients ranges from <10% to >80%, depending on 
the degree of cardiac damage32,36. In endemic areas of Chagas disease, infection is 
estimated to account for 41% of heart failure cases, and Chagas etiology may be 
responsible for 6.3% of these deaths37.  
 
13 
 
 
Prevalence worldwide–  
In 2010, due to political/economic reasons, migration from 17 countries endemic 
to Chagas disease was observed and Chagas disease became a global public health 
problem38. It has been estimated that over 8 million people are infected worldwide39 
[number changes to 10 million depending on the sources]; with an estimated 300,000 
individuals infected in the United States,  80,000 in Europe and Western Pacific Region, 
5,500 in Canada, 3,000 in Japan, and 1,500 in Australia30,40. Figure 7 demonstrates the 
global distribution of Chagas disease in 2010. Estimates of the number of T. cruzi-infected 
individuals in non-endemic countries such as Australia, Canada, Spain, and the United 
States, were calculated by taking legal immigrant population from endemic countries and 
their prevalence of disease into consideration40.  
 
 
 
Figure 7) Global distribution of Chagas disease cases, based on official estimates, 2006-2010. Source: 
World Health Organization, 2010,WHO-Map98. 
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  Transmission in the U.S.A– 
In the United States, T. cruzi infection is considered a neglected tropical disease, 
however, it has become a growing threat due to increased globalization. It is approximated 
that more than 300,000 (Figure 8) people in the United States are infected with T. cruzi, 
placing the U.S. second in prevalence after Latin America10,41.  This estimate does not take 
into account undocumented immigrants and congenital infections. Possible vector 
transmissions in the U.S. has been monitored, especially in southern regions where 11 
triatomine vectors species have been reported to maintain T. cruzi enzootic cycles11. These 
triatomines are present across the southern tier from the Pacific to Atlantic coasts. The 
greatest diversity of vector species was found in the southwest; particularly Texas, Arizona, 
and New Mexico; detected by the presence of T. cruzi-infected wild mammals11.  
 
Figure 8) Prevalence of Chagas disease imported cases in non-endemic countries. Source: Chagas disease. 
Rassi A, et al. 10 Lancet 2010; 375:1388-402. 
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To prevent transmission into the U.S., current FDA recommendations are to screen 
all blood donors using one of the two FDA-approved screening tests - blood testing is done 
through Radioimmunoprecipitation Assay (RIPA) to detect specific antibodies in serum42. 
Organ procurement organizations now perform selective or universal screening of donated 
organs for the presence of T. cruzi42,43. 
Animal reservoirs in the U.S.A. – 
In the Western United States, woodrats are the most common reservoir but other 
rodents such as raccoons, skunks, and coyotes are also infected11.  In the Eastern United 
States, raccoons, opossums, armadillos, and skunks are the most common reservoirs11. 
Triatoma gerstaeckeri is one of the most frequently collected and tested vector species in 
the United States11. The lower prevalence of Chagas disease in United States is attributed 
to the triatome species in this areas having delayed defecation (lowering transmission 
efficiency), as well as to the relatively better housing conditions that minimizes contact 
with the vector44,45. In total, seven autochthonous vector-borne human infections, five 
instances of organ-derived transmission from three donors, and five transfusion-associated 
T. cruzi infections had been documented in the States as of 201111. All the transfusion-
associated infections were associated with recipients who had underlying malignancies and 
were immunosuppressed11. 
Economic impact in the U.S.A.– 
Chagas disease could also be an important economic impact in the U.S. An 
individual in the U.S. with chronic Chagas Disease is estimated to accrue an annual health-
care cost of $2,161. This makes the U.S. second after Brazil in Chagas-disease-related 
 
16 
 
health care costs. At an estimated burden of 27,590 DALYs lost the U.S. is the second 
highest region for morbidity after Latin America2. 
Clinical Manifestations 
Chagas disease has two main stages - acute and chronic.  
Acute –The acute phase of infection can last between 6-8 weeks. While it is usually 
asymptomatic, some cases may present with malaise, enlarged liver/spleen/lymph nodes, 
prolonged fever, and subcutaneous oedema. At the site of the wound left by the insect 
vector, a chagoma may form if there is vector-borne transmission with T. cruzi entry 
through the skin. A chagoma is a reddened indurated area that may reach several 
centimeters in diameter and become very painful.  The lesion typically subsides over a 
period of 2 to 3 months13. It is also known as a Romaña sign if it occurs in the ocular 
mucous membrane10. In the first weeks after infection, similar lesions to the initial chagoma 
may also appear elsewhere in the body13. 
Chronic – From these acute cases, ~70% never develop subsequent clinical 
manifestations.  Presumably these patients are able to clear the infection. However, ~30% 
transition to the chronic phase of the disease that can persist for 10 to 30 years. The clinical 
manifestations diverge depending on the geographical area the disease is acquired, 
probably due to a difference in parasite strains10,46. The chronic phase ranges from 
asymptomatic (known as intermediate-chronic phase/ intermediate form) to severe illness 
and premature death. Manifestations include lesions of the autonomous nervous system in 
the heart, colon, esophagus, or the peripheral nervous system; cardiac alterations, digestive 
pathology, or neurological alterations10. When clinical manifestations are present they are 
divided into three major forms: cardiac, digestive and cardio-digestive10. The cardiac form 
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is the most serious and it accounts for 20-30% of the cases, making it the most frequent47. 
It includes heart abnormalities leading to cardiomyopathy, thromboembolism, cardiac 
failure, and sudden death. Typical heart abnormalities associated with Chagas disease are 
a combination of right bundle branch block and left anterior fascicular block, with heart 
failure more often related to late manifestations, and sudden death being the main cause of 
disease-mediated mortality10.  
The digestive form of Chagas is seen in 10-15% of chronic cases. This form is a 
progressive degeneration of the digestive tract leading to megaesophagus, megacolon, or 
both. The cardiodigestive form includes cases that have both the cardiac and digestive 
forms.  
Around 10% of the infants from T. cruzi-infected mothers are born with 
congenital  Chagas’ disease5,48. Symptoms in congenitally infected infants include low 
Apgar score (health score for newborns standing for “Appearance, Pulse, Grimace, 
Activity, and Respiration”), fever, anemia, hepatosplenomegaly, hypotonicity, 
prematurity, and low birthweight10.  Infection also associated with abortion and 
placentitis10. 
Congenital infection occurs in 1-10% of these infants and while most are also 
asymptomatic, a small portion cause severe morbidity presenting with anemia, 
hepatosplenomegaly, or respiratory insufficiency49. A more severe form of the disease is 
also observed in children younger than 5 years, and symptoms can include involvement of 
the central nervous system13. Immunocompromised infants have severe symptoms such as 
increased parasitemia (or infection reactivation in previously asymptomatic patients), 
severe myocarditis, and increased mortality. Cases of T. cruzi/HIV co-infections can also 
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lead to infection reactivation and sever neurological symptoms, often leading to 
misdiagnosis13,31. In people with HIV/AIDS, meningoencephalitis is the most frequent 
manifestation50. Also of note, since HIV-positive patients have weak antibody responses, 
serological diagnostics are not effective31. 
 
Immune response to T. cruzi 
Acute – The immune response to T. cruzi infection is linked to the life cycle of the 
parasite.  The consensus opinion is that T. cruzi emerging from infected cells and entering 
the bloodstream in high numbers is the trigger of the clinical manifestations observed 
during acute phase of infection. Antibodies recognize a spectrum of T. cruzi antigens. 
These antibodies are consistently present in infected subjects, with higher titers being 
observed in the acute phase51,52. The anti-T. cruzi antibodies are able to kill the extra 
cellular forms of the parasite by complement-mediated lysis51 and in some individuals 
these antibodies are sufficient to eliminate the parasite,52.  However, antibodies are not able 
to completely clear the intracellular stages of the parasite. An anti-T. cruzi CD8 T cell 
response has been identified, however, it does not appear to be strong enough to completely 
eliminate the parasite, but has been implicated in keeping the parasite under control53. Once 
inside muscle cells, heart tissue, the digestive system, or phagocytic cells, inflammatory 
lesions lead toward the chronic stage7. The parasite is able to evade the immune response 
by a combination of cell invasion, antioxidant enzymes, surface molecules and other 
compounds53. It has also been observed that the oxidative stress induced in infected 
macrophages, instead of being detrimental to parasite survival, favors persistence of the 
intracellular amastigote stage53.  
 
19 
 
Chronic – The immune mechanisms associated with the chronic phase of infection 
is mostly unknown. It has been found that inflammatory lesions formed are dependent on 
CD4 T cells+, CD8 T cells+, IL-2, and IL-4; leading to heart failure, dilatation of the 
esophagus and colon7. It has also been proposed that this continuous inflammation causes 
an autoimmune-like disease due to cross-reactive epitopes that are common to molecules 
expressed by both T. cruzi and the host (also known as immune mimicry) 51.  
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Diagnosis 
 
Diagnosis of T. cruzi depends on the phase of infection and traditionally relies on 
direct demonstration of trypomastigotes in blood or indirect detection of amastigotes in 
tissues with serological testing, hemoculture, or xenodiagnosis, and other methods.  
 Acute infection – The detection of the acute infection is based on the microscopic 
detection of trypomastigotes in blood. Microscopy techniques, including giemsa-stained 
thin and thick whole blood films or buffy coat preparations (microhematocrit technique), 
or serum precipitate (Strout technique) are used5,10,32. If positive for the acute phase, 
additional tests are used to determine whether the disease has entered the chronic phase.  
Congenital – For congenital infections, diagnosis of the acute infection is based on 
the microscopic detection of trypomastigotes in blood through microhematocrit tests with 
cord blood or peripheral blood. Tests from neonates during the first month of life are 
recommended 10,54. IgG serology at 6–9 months of age is also recommended when 
microhematocrit results are repetitively negative or not done early in life10,55. PCR has also 
been used for early detection by amplifying T. cruzi DNA in blood samples10,56.  
Chronic – Diagnosis of chronic T. cruzi infection is made after consideration of the 
patient's clinical findings as well as by the likelihood of being infected, such as having 
lived in an endemic country, or through additional tests after acute phase confirmation, 
such as an ECG (electrocardiogram), chest X-rays, echocardiograms, abdominal X-rays, 
and upper endoscopy57.  For diagnostic confirmation, two different serological tests are 
required since no single, gold standard reference test is available5,55,58. During the chronic 
stage, trypomastigotes are usually not found circulating in blood thus serologic testing 
based on parasite-specific IgG antibody detection.  Serological tests include Indirect 
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with epitopes found on molecules from other pathogens and possible false negative 
diagnostics46,9,60,64. Meanwhile, cultures and xenodiagnosis, though more affordable and 
proven to provide good sensitivity, can be inconvenient and test results take a long period 
of time to obtain.  
Diagnosis takes time and effort, especially in non-endemic countries, where 
personnel are not trained to recognize the disease. A good summary of the process used in 
the detection chronic phase infection is presented by Molina et al. in Figure 95: In 
summary, when a patient is suspected to have chronic infection (concluded from clinical 
history and symptoms) two serological analyses are required. When results are 
inconclusive, a third test is required from a reference laboratory for confirmatory results. 
Once confirmed, patients undergo a clinical evaluation (ECG examination, and 
echocardiography) to determine the phase of infection and recommended treatment follow-
ups 5. 
With current detection methods, there are also difficulties differentiating between 
newly acquired and past infections, since anti-T. cruzi IgG does not allow you to 
discriminate between an active infection or previous exposure to the parasite. Antibodies 
may still be circulating after successful treatment or undetectable, depending on tests used, 
method of sample collection, time after treatment, etc. 5,65.  
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Figure 9) Chronic Chagas Disease Patient Assessment. Source: Chagas disease. Molina J, et al. The Lancet 
2018; 391:10115-825. 
 
24 
 
Nucleic Acid-based detection of T. cruzi 
An alternative diagnosis method is the detection of T. cruzi DNA as cell-free DNA 
(or cfDNA). Detection of cell-free DNA has potential for being a painless, convenient, 
non-invasive, and cost-effective approach that can be used in large-scale epidemiological 
screening programs62. While cfDNA detection is a relatively new concept for parasite 
diagnosis, it has a big potential of improvement and applications, and is already being used 
as an efficient biomarker in the fields of parental diagnosis (cell free fetal DNA or 
cffDNA), oncology (circulating tumor DNA or ctDNA), and as a method to identify fetal 
genetic disorders62,66. As the name suggests cfDNA are degraded DNA fragments found 
extracellularly mainly in circulation. While its origin is still unclear, it is thought to mainly 
originate from cells that undergo apoptosis65. It can also be found in urine, saliva, sputum, 
peritoneal fluid, synovial fluid, lymph, and amniotic fluid,62. The size of DNA fragments 
found in cfDNA range from 20 bp to 20 kbp depending on mechanism of release67. Cell-
free DNA has been used to diagnose a number of human parasitic infections including 
Plasmodium, Schistosoma, Trypanosoma, Wuchereria spp, and Leishmania62. 
With advances in technology and techniques, new detection methods are arising. 
Such is the case of a quantitative real-time PCR (qPCR) study by Ramirez et al.68 that 
targeted either Sat-DNA or k-DNA for a large number of blood samples from acute and 
chronic patients. While the clinical sensitivities of Sat-DNA and k-DNA assays were 
~80%, both approaches were highly specific and reproducible. Also important to note is 
that PCR molecular techniques have been demonstrated to show positive results days to 
weeks before circulating trypomastigotes are visible by microscopy of peripheral blood49. 
Many other PCR strategies have also emerged for identification of T. cruzi DNA from 
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serum7–10.  However, while these serum PCR-based assays have been found to be 
sufficiently specific, so far they are not commercially available and cannot be used for 
clinical diagnosis (due to sensitivity and performance variations); so far they are only used 
in cases where serological results are inconclusive 5,64,69,70. Variations are caused by factors 
such as differences in DNA source (i.e. blood, tissue), collection, processing, sample 
volume, storage, parasitemia levels, and DTU variations; a more consistent protocol needs 
to be resolved and followed69.  Also, this type of DNA-based molecular diagnostic method 
can be expensive and difficult to implement in endemic areas with limited infrastructure. 
That is why we have focused our attention onto urine samples. A proportion of the 
cfDNA in the serum passes through the kidney glomerular barrier and is detectable in the 
urine by PCR amplification71. Two groups of cfDNA are found in urine: large fragments 
(>1000 bp) originating from cells of the lower urinary tract, and small fragments (around 
150-250 bp) probably originating from circulation, also known as transrenal-DNA or Tr-
DNA72. We selected filtered urine samples since previous work done in the Shiff lab, by 
Ibironke73, Lodh83 and Toribio84, demonstrated that when urine is filtered, the DNA is 
stable on the filter for extended period of time. Ibironke and co-workers demonstrated this 
technique to be sensitive and specific in the detection of Schistosoma haematobium DNA 
– heretofore an infection only diagnosed through clinical assessment and microscopic 
detection of eggs in stool or urine (chronic and asymptomatic infections were often 
missed). The use of filters also facilitated specimen collection and transportation. Using a 
similar approach, detecting T. cruzi DNA through Tr-DNA PCR amplification presents a 
possibility for detection of Chagas disease in chronic phase, as well as early detection of 
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congenital disease, treatment-monitoring, inconclusive serology results elucidation, and 
management of immunosuppressed patients. 
 
Treatment 
 Treatment of Chagas disease focuses on killing the parasite and managing the 
disease symptoms. Treatment with antitrypanosomal drugs is urgently recommended to 
patients that demonstrate the acute phase of the disease, congenital infection, and 
immunocompromised patients74. Drugs may also be offered to patients younger than 50 to 
slow disease progression, however, once the chronic phase is reached, medication alone is 
no longer curative and additional treatment is advised depending on symptoms (patients 
can be referred to cardiologists, gastroenterologist, or an infectious disease specialist)13,74. 
It has also been observed that effectiveness of treatment decreases with time from primary 
infection 5,75,10. For heart related complications, treatment may include peacemakers, 
surgery, or heart transplant 57. For digestive complications, diet modification, medication, 
corticosteroids, or surgery may serve as treatment57. For these reasons early detection and 
speedy treatment is key.  
While no T. cruzi-specific treatments are currently available, two licensed 
antitrypanosomal drugs are available that have action on the blood forms of the parasite: 
Nifurtimox and benznidazole. Both are oral compounds that require prolonged 
administration and may display severe adverse effects, with safety and efficacy profiles far 
from ideal5,76. They cannot be used to treat pregnant women, are usually not recommended 
for patients over 50 years of age, and only show high efficacy when administered at onset 
of infection10,77,78.  
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Nifurtimox was the first drug used against T. cruzi. It requires oral administration 
of 3-4 doses (8-10 mg/kg-adults; 15 mg/kg-children) throughout a 60-90-day period. 
Adverse effect frequency ranges from 43%-97.5%5 including psychic alterations, digestive 
manifestations such as nausea or vomiting, anorexia, loss of weight, excitability, 
sleepiness, and occasionally intestinal colic and diarrhea76. Causing treatment to be 
discontinued in 14.5%-75% of cases5. 
 Benznidazole is usually preferred since it is usually better tolerated by patients. It 
requires oral administration of 2-3 doses (5-10 mg/kg) throughout a 60-day period, with 
higher doses recommended in cases of meningoencephalitis5. Adverse effects include skin 
manifestations (e.g., hypersensitivity, dermatitis with cutaneous eruptions, generalized 
oedema, fever, lymphadenopathy, articular and muscular pain), with depression of bone 
marrow, thrombocytopenic purpura and agranulocytosis76. The drug shows evidence of 
neurotoxicity, ovarian toxicity, testicular damage, and harmful effects to colon, esophagus, 
adrenal, and mammary tissue76 resulting in treatment to be discontinued in 9%-29% of 
cases5. It is the first drug approved (2017) in the U.S. by the FDA for  T. cruzi infections 
(only approved for patients 2 to 12 years of age)61.  
Due to the adverse effects new treatments are required. These treatments also do 
not provide 100% clearance of parasite, they are effective against extracellular 
trypanosomes not against intracellular amastigotes, and cases of re-emergence of disease 
do occur79,80. 
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II. Study Aims  
 
We hypothesis that cell-free T. cruzi DNA is accessible from the urine of patients 
as Tr-DNA and the PCR-based detection of T. cruzi Tr-DNA is a sensitive and specific 
measure of both the acute and chronic phases of Chagas disease.  
 
Rationale. As mentioned in the introduction, the current methods of PCR analyses focus 
on detection of T. cruzi DNA from serum, taking advantage of repeat genome sequences 
from Sat-DNA and k-DNA. We used a similar approach, however, this time adapting 
primers in an attempt to optimize T. cruzi Tr-DNA detection from urine samples.  
We targeted the small repeat sections of T. cruzi Sat-DNA (195 bp; Tc Sat-DNA) 
and kDNA (conserved 124 bp and variable 330 bp; Tc k-DNA) that could be present in 
patient’s urine as Tr-DNA (150-250 bp). kDNA is the T. cruzi mitochondrial genome that 
contains approximately 10,000 copies of a minicircle DNA.  Each minicircle contains four 
regions of highly conserved DNA. For this reason, primers were selected to target different 
sections of T. cruzi kDNA: Primers 121-122 targeting the variable domain found between 
two conserved regions of the kDNA, and primers Minicon-1 and Minicon-2 targeting the 
conserved regions of the kDNA. Another set of primers was selected to target the Sat-DNA 
mini-satellite region, present in ~120,000 copies and representing 10% of the genome with 
a 195 bp repeat sequence. A nested PCR approach with primers TCZ1, TCZ2, TCZ3, and 
TCZ 4 was used.  
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III. Methods 
 
In the following chapters, I will outline the process by which we tested our 
hypothesis. From sample collection and processing, to the DNA amplification and different 
protocols used. 
 
Preliminary Studies  
Study Population. Five samples, extracted from filtered urine, were obtained from an 
ongoing investigation on patients from Argentina with Strongyloides who were also 
suspected to being co-infected with T. cruzi. Four frozen urine samples, previously stored 
at -80°C, were provided by the Gilman lab (Johns Hopkins University, Bloomberg School 
of Public Health) as two ~40 mL samples collected from adults and two 5 mL samples 
collected from newborns of infected mothers. 
Frozen Urine Extractions. To extract DNA from frozen urine, samples were first thawed 
at room temperature, after which they were filtered through 12.5 cm Whatman No. 3 
(Whatman International, Maidstone, UK) filter paper and extracted following method 
described below. 
The remaining two frozen urine samples were first thawed at room temperature 
after which Enk’s81 salting and resin extraction protocol was followed. Briefly, the two 
samples were adjusted to 40 nM EDTA, then heated at 100°C in a water bath for 10 
minutes. After that, 5 M NaCl (in a volume of 1/10 of the sample volume) was added to 
each tube. The tubes were shaken vigorously for 15 seconds, placed on ice for 1 hour and 
centrifuged for 10 minutes at 4,000 rpm. The supernatant was transferred to another tube, 
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shaken vigorously for 15 sec and centrifuged for 10 minutes at 4,000 rpm. The supernatant 
was transferred to another clean tube, and absolute ethanol (two times the sample volume) 
was added. The DNA was then precipitated at -20°C for at least 2 hours. The DNA was 
removed with a pipette, transferred to a 0.5 mL microcentrifuge tube and washed in 200 
μL 70% ethanol. The tubes were centrifuged again for 20 minutes at 14,000 rpm. The 
pellets were dried and suspended in 100 μL of DNAse free water and 100 μL of InstaGene 
matrix® resin (BioRad). Samples were incubated at 56°C for 30 minutes and 100°C for 8 
minutes, vortexed at high speed for 10 seconds and centrifuged at 14,000 rpm for 3 
minutes81. The supernatant was transferred to a new tube and DNA concentrations were 
measured using the Nano Drop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE) and were stored at -20°C. 
DC Cohort Sample 
Study Population. Forty urine specimens were collected from Chagas disease patients in 
the DC and Virginia area as part of a collaboration with Dr. Robert Gilman (Department 
of International Health, BSPH, JHU) and Dr. Rachel Marcus (MedStar Health & Vascular 
Institute). The individuals tested belonged to a cohort in a study titled “Chagas Disease and 
cardiac abnormalities in the Washington Metropolitan Area”.  Informed written consent 
was given for both sample collection and biorepository sample storage (consent forms were 
explained both in English and Spanish), samples were kept confidential with unique 
identification codes (IRB 00006713), and blind testing was followed to prevent bias.  
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Sample Filtration. All participants provided ~50 mL of urine in a plastic cup containing 
EDTA (for a final concentration of 40 mM, pH 8). Urine was then passed through 12.5 cm 
Whatman No. 3 (Whatman International, Maidstone, UK) filter paper, marked for subject 
identification and folded into a cone for easier filtration and concentration. The cones were 
mounted in single use falcon tubes to filter the urine at room temperature (Figure 10). After 
the urine had passed through the filter, filter discs were then unfolded and left to dry at 
room temperature before being packed with a desiccant onto individual plastic sleeves and 
stored at 4°C.  
 
DNA Extraction. To extract DNA from the filter paper, 10 punches (each 1/4”) from the 
inner quadrant of the cone were taken (Figure 11). The paper puncher was cleaned with a 
10% bleach solution and dried between each sample to avoid contamination. All 10 paper 
discs from a given sample were placed into a 1.5 mL Eppendorf tube and 400 µL of 
nuclease-free water was added. The tubes were then incubated at 95°C for 10 minutes and 
then mounted in a rotating water bath at room temperature overnight (~16-18 hours). The 
water-DNA solution was then transferred to Qiagen QIAmp 2 mL column, and DNA was 
Figure 10) Filter urine process. A. Folded filter cone, B. Mounted filters, C. Drying. 
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precipitated and concentrated using QIAmp DNA Blood Mini Kit (Qiagen, MD) following 
the manufacturer’s protocol. DNA concentrations were measured using the Nano Drop 
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and were stored 
at -20°C. 
 
 
PCR Controls. T. cruzi genomic DNA (gDNA) was used as positive control. Genotyped 
as DTU II, ND, the control sample was provided by the Gilman group as a clot from a 
blood culture that was artificially infected with T. cruzi. To extract the DNA from the 
coagulate, the QIAmpDNA Mini Kit (Qiagen, MD) was used following the manufacturer’s 
protocol for DNA purifications from tissues (steps 1-2c-3), and DNA purification from 
blood. DNA concentrations were measured using the Nano Drop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE) and were stored at -20°C. 
Urine samples obtained from individuals with clinical and serological negative results were 
used as negative controls. All reagents without DNA in each reaction were subject to 
amplification cycles as quality control. 
  
Figure 11) Filter 
placement. A. cone 
shaped filter with 
dashed line 
representing section in 
contact with urine were 
products accumulate. 
B. Inner quadrant 
(dashed line) in contact 
with urine contains 
most of the 
concentrated DNA. 
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Primer building. The 124 bp minirepeat reported for T. cruzi k-DNA (Degrave et al.24) 
was used as a query in BLAST using the non-redundant database of NCBI.  Matches 
showing e-values < 0.001 and covering at least 90% of the query sequence were retained 
for further use. Based on this, k-DNA primers Minicon-1 (5’-TTT GGG AGG GGC GTT 
CAA AT-3’) and Minicon-2 (5’-ACA CCA ACC CCA ATC GAA CC-3’) were designed 
using PrimerBlast (PubMed). Primer properties and specificity for T. cruzi k-DNA were 
verified using BLAST search against non-redundant databases (PubMed, TriTryp). 
PCR.  All 40 DNA samples ranged in concentration ~1-3 ng/µL. 4 µL of sample DNA was 
used as PCR template.  For the positive control, 1 µL of gDNA was used as template. 
Amplification was conducted in 0.2 mL PCR tubes in a thermal cycler (SimpliAmpTM 
Thermal Cycler, lifetechnologiesTM). Different primer sets were tested. See Table 2 for a 
summary of primers used.  
Primer Target Amplicon Reference 
121    5'-AAA TAA TGT ACG GGK GAG ATG 
CATGA-3' 
k-DNA 330bp Shijman70 
122 5'-GGT TCG ATT GGG GTT GGT GTA ATA 
TA-3' 
Minicon-1 5’-TTT GGG AGG GGC GTT CAA AT-3’ 
k-DNA 113bp This work 
Minicon-2 5’-ACA CCA ACC CCA ATC GAA CC-3’ 
TCZ1 5'-CCG ACG TCT TGC CCA CAC GGG 
TGCT-3' 
Sat-
DNA 149bp Martins
82 
TCZ2 5'-CCT CCA AGC AGC GGA TAG TTC 
AGG-3' 
TCZ3 5'-TGC TGC AST CGG CTG ATC GTT TTC 
GA-3' 
TCZ4 5'-GAR GST TGT TTG GTG TCC AGT GTT 
GTGA-3' 
Table 2) Summary table of primers including target section of T. cruzi DNA, amplicon and reference. 
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In order to amplify the k-DNA variable domain, primers 121 (5'-AAA TAA TGT 
ACG GGK GAG ATG CATGA-3') and 122 (5'-GGT TCG ATT GGG GTT GGT GTA 
ATA TA-3') were used, generating a 330 bp fragment70. PCR protocol was adapted (from 
Shijman et al. 70) for a total PCR reaction volume of 15 µL. Containing 7.5 µL of PCR 
Master Mix [2X, Promega, Madison, WI], 0.75 µL of each of the amplification primers 
(10 µM), 0.75 µL of 25 mM MgCl2, and 3.25 µL of DNAs-free water to complete final 
volume. Thermal profile settings were:  
 
Minicon-1 (5’-TTT GGG AGG GGC GTT CAA AT-3’), Minicon-2 (5’-ACA CCA 
ACC CCA ATC GAA CC-3’) were used to amplify kDNA minirepeat section of the 
conserved domain, producing a 113 bp fragment. The PCR reaction was prepared to a final 
volume of 15 µL. Containing 7.5 µL of PCR Master Mix [2X, Promega, Madison, WI], 
0.75 µL of each of the amplification primers (10 µM), 2 µL of 25 mM MgCl2, and 2 µL of 
DNAs-free water to complete final volume. Thermal profile settings were: 
94°C 3min 
97.5°C 1min 
64°C 2min 
94°C 1min 
62°C 1min 
72°C 10min 
X1 
X2 
X37 
X1 
94°C 10 min 
93°C 1min 
58°C 1min 
70°C 1min30s 
70°C 10min 
  
X1 
X35 
X1 
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Nested-PCR (N-PCR) was used in order to amplify a 149 bp fragment from the Sat-
DNA minirepeat domain82. Utilizing primers  TCZ1 (5'-CCG ACG TCT TGC CCA CAC 
GGG TGCT-3') and TCZ2 (5'-CCT CCA AGC AGC GGA TAG TTC AGG-3') for the first 
reaction and TCZ3 (5'-TGC TGC AST CGG CTG ATC GTT TTC GA-3') and TCZ4 (5'-
GAR GST TGT TTG GTG TCC AGT GTT GTGA-3') for the second reaction82. For the 
first step, the protocol was adapted (from Martin et al.82) for a total PCR reaction volume 
of 15 µL. Containing 7.5 µL of PCR Master Mix [2X, Promega, Madison, WI], 0.75 µL of 
each of the amplification primers (10 µM), 1.5 µL of 25 mM MgCl2, and 2.5 µL of DNAs-
free water to complete final volume. For the second step, 7 µL of previous PCR product 
was used as template for the second amplification, for a total final volume of 18 µL. 
Containing 7.5 µL of PCR Master Mix [2X, Promega, Madison, WI], 0.75 µL of each of 
the amplification primers (10 µM), 1.5 µL of 25 mM MgCl2, and 2.5 µL of DNAs-free 
water to complete final volume. Thermal profile settings were:  
 
 
95°C 5min 
95°C 30s 
60°C 30s 
72°C 1min 
95°C 30s 
65°C 30s 
72°C 1min 
70°C 10min 
X1 
X5 
X1 
X25 
Step 1 
94°C 5 min 
94°C 40s 
55°C 40s 
72°C 1min 
72°C 7min 
  
X1 
X25 
X1 
Step 2 
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Analysis of PCR Products by Agarose Gel Electrophoresis.  The PCR products were 
separated and sized on a 2% agarose gel. The gels were then post-stained with ethidium 
bromide solution (0.5 µg/mL) for 30 minutes, and de-stained in fresh distilled de-ionized 
water for 20 minutes with gentle agitation. The gel was then visualized with UV light. A 
ladder marker of 100 bp (New England BioLabsInc.) was used to estimate band sizes. 
DNA Band Extraction and Sequencing. Resulting bands from positive samples were 
extracted from the agarose gel using the Monarch Nucleic Acid Purification kit 
(BioLabsInc.), following the manufacturer’s protocol. 
The eluted PCR DNA from positive samples were prepped for sequencing as 
recommended by Macrogen (Macrogen USA, MD), and sent separately (not premixed) 
with their respective primers to allow for sequencing conditions to be altered as needed. 
Results were then verified using BLAST search against non-redundant databases 
(GenBank, TriTryp). Positive samples were also run through a tape station (D1000 Screen 
Tape) to confirm the size of bands extracted (samples run and analyzed by Anne Jedlicka).  
Bioinformatic analysis. To determine whether bands of different sizes found in the same 
sample were indeed fragments of repeats sections, samples were aligned and compared 
both to their corresponding positive controls and other bigger bands found in the same 
sample. Archived BLAST alignment results from samples were also aligned against the 
positive control using ClustalX with default settings. 
Serology Samples. Serum samples were also collected from the patients who volunteered 
urine samples.  The serum samples were processed and analyzed by Dr. Gilman’s group 
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and the results of the tests were provided for comparison with the Tr-DNA results from 
each patient. A summary of the serology tests used can be seen in Table 3.  
 
Test Test Name Approved Description (Antibody/Antigen) 
RT Chagas Detect Plus FDA Immunochromatographic strip assay to 
detect anti-T. cruzi IgG. Only approved 
when coupled with a different serological 
test. 
ELISA Hemagen Chagas 
kit 
FDA Detection of anti-T. cruzi IgG.  Lysate 
antigen of the epimastigote and 
amastigote forms of strain Y (DTU II) 
and CL (DTU VI) 
ELISA Chagatest EIA 
Recombinant v.3.0 
FDA Detection of anti-T. cruzi IgG that 
recognize the five recombinant antigens 
(SAPA, 1, 2, 13, 30, 36) 
IFA  CDC Detection of anti-T. cruzi IgG using a 
fixed preparation of epimastigotes.  Time 
consuming, and has cross-reactive with 
Leishmaniasis 
IHA Chagas Polychaco 
Kit 
CDC Detection of anti-T. cruzi IgG against 
trypomastigote excretory-secretory 
antigens 
Table 3) Summary of serology tests run. (RT- Rapid Test) (ELISA- enzyme-linked immunosorbent assay) 
(IFA- Immunofluorescent-Antibody Assay) (IHA- Indirect Hemagglutination Assay). 
 
Statistical analysis. A Pearson correlation test, utilizing Graph Pad Prism, was done to 
determine if there was significant correlation between urine volume and DNA 
concentration. To illustrate consensus between tests run, Venn diagrams were constructed. 
Results were recorded for all tests and converted into numerical values (1=positive, 
0=negative) for analysis of concordant pairs between tests.  
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IV. Results 
 
Preliminary Tests and Optimization 
Preliminary Sample Selection. To determine whether previously stored urine samples, at 
-80°C, could be used for PCR analysis, four frozen samples were provided by the Gilman 
group. Two samples (40 ml) were thawed, filtered, and DNA was extracted following the 
same protocol as the other filtered samples. The smaller two samples (5 mL) required a 
different method of DNA extraction. None of the four samples extracted demonstrated 
sufficient quality total DNA to perform PCR analysis.  We concluded that freezing urine 
samples was not a proper method of preserving Tr-DNA. 
For this reason, five filtered urine samples were provided by an ongoing 
investigation on patients from Argentina with Strongyloides who were suspected to being 
co-infected with T. cruzi. All samples and controls contained 1 ng/µL DNA concentration. 
These five filtered samples were used for preliminary and control runs. 
 
Agarose Gel Electrophoresis Optimization. One of the issues encountered early on in our 
study was the ability to easily determine which samples were PCR positive by gel analysis.  
To enhance the ability to discriminate between positive and negative samples we revised 
the approach that we used for staining and visualizing the PCR products.  The sensitivity 
between two different ethidium bromide (EtBr) protocols was compared to improve 
sensitivity (Figure 12). Both gels were prepped with 2% agarose and run with two water 
controls (W), two urine filtered samples (D-E), a negative control (-C), a positive control 
(+C), and 100 bp ladder for sizing. All samples and controls contained 1 ng/µL DNA 
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concentration. In gel A, EtBr (0.5 µg/mL) was included in the dissolved agarose during gel 
formation and allowed to set, after which samples were loaded and run (A, Figure 12). In 
gel B, samples were run through the agarose gel first, followed by a staining step with EtBr 
solution (0.5 µg/mL) for 30 minutes and de-stained procedure in water for 20 minutes with 
gentle agitation (B, Figure 12). The post-run staining method was demonstrated to be the 
more sensitive technique for visualizing the PCR results.  The post-run staining protocol 
was used for all subsequent experiments. 
 
Primer Selection. In order to determine whether existing primers (previously determined 
sufficiently specific and sensitive to detect T. cruzi DNA in serum samples) could be used 
to detect T. cruzi DNA from urine samples, five primer sets that produced small amplicons 
(<400 bp) were selected from different sources. Three of the primer sets targeted Sat-DNA 
and two targeted k-DNA (Table 4).  
  
L W W D E -C +C L W W D E -C +C 
Figure 12) Comparison of 
2% agarose gels EtBr 
staining protocols. 
A. Pre-run staining 
B. Post-run staining.   
L= 100 bp Ladder, W=water 
control, D-E = urine filtered 
samples, -C= negative 
control, +C= positive control 
(gDNA). 
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The five primer sets were compared following a control PCR protocol. The top 
performing primers were selected for further studies. Control PCR’s were set up with two 
water controls (W), two urine filtered samples (D-E), a negative water control (-C), a 
positive control consisting of T. cruzi genomic DNA at 5.3 ng/µL (+C), and 100 bp ladder 
for sizing were run for each primer set, following thermal protocols as instructed by each 
of the primer sources.  
  
 Primer Target Amp. Ref. 
C
on
ve
nt
io
na
l P
C
R
 
121    5'-AAA TAA TGT ACG GGK GAG ATG CATGA-3' k-
DNA 
330 
bp Shijman 
70 
122 5'-GGT TCG ATT GGG GTT GGT GTA ATA TA-3' 
P67 5’-TGGTTTTGGGAGGGGCGTTCAAATTT-3’ k-
DNA 
122 
bp Avila
99 
S34A 5’-TATATTACACCAACCCCAATCGAACC-3’ 
cruzi-1 5'-TGAATGGYGGGAGTCAGAG-3’ Sat-
DNA 98 bp Ramirez
100 
cruzi-2 5'-ATTCCTCCAAGMAGCGGAT-3’ 
TCZ-F 5'-GCTCTTGCCCACAMGGGTGC-3' Sat-
DNA 
182 
bp Shijman 
70 
TCZ-R 5'-CCAAGCAGCGGATAGTTCAGG-3' 
nP
C
R
 
TCZ1 5'-CCG ACG TCT TGC CCA CAC GGG TGCT-3' 
Sat-
DNA 
149 
bp Martins
82 
TCZ2 5'-CCT CCA AGC AGC GGA TAG TTC AGG-3' 
TCZ3 5'-TGC TGC AST CGG CTG ATC GTT TTC GA-3' 
TCZ4 5'-GAR GST TGT TTG GTG TCC AGT GTT GTGA-3' 
Table 4) Preliminary primers, target T. cruzi DNA, amplicon and reference obtained from. nPCR= 
nested PCR, Amp. =Amplicon, Ref. =Reference. 
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Of the 5 primer sets tested, TCZ1-TCZ4 (nPCR) and 121-122 were the most 
sensitive (data not shown). The nested PCR (nPCR) targeting Sat-DNA resulted in the 
predicted band size of 149 bp in the genomic DNA (+C) and from one of the filtered urine 
samples (D, Figure 13), the other filtered sample was negative. Primers 121-122, which 
targets the k-DNA minicircle repeat, produced the correct band size of 330 bp for the T. 
cruzi gDNA positive control (+C), but different sized bands for one of the filtered urine 
samples (sample E, Figure 13), at 124 bp, 250 bp, and 270 bp. The 121-122 primer set did 
not amplify products from sample D.   
Figure 13) 2% agarose gel of primers: 121-122 and TCZ1-TCZ4: 121-122 (330bp) and nPCR (149 bp) 
L= 100 bp Ladder, W=water control, D-E = urine filtered samples, -C= negative control, +C= positive. 
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The thermal profile for primers 121-122 was optimized until clearer bands were 
observed and ran with the 5 filtered samples. Four out of the five samples were negative, 
with only sample E being positive. Still, the differently sized bands were observed in 
sample E (Figure 14) while the positive control (gDNA) demonstrated its corresponding 
primer amplicon band at 330 bp. Each of the different sized bands (124 bp and 270 bp) 
were individually extracted and sent to sequencing and identified using BLAST. These 
results demonstrated that, even though sample Tr-DNA and gDNA from the +C produced 
differently sized bands, primers 121-122 could still be used to detect T. cruzi k-DNA from 
filtered urine samples. 
Figure 14) 2% agarose gel of optimized primers 121-122: (330bp) L= 
100 bp Ladder, W=water control, A-E = urine filtered samples, -C= 
negative control, +C= positive control (gDNA). 
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New Primer building. While primers 121-122, targeting the minicircle variable domain, 
produced positive results, the bands observed from the filtered urine samples contained 
bands with sizes that were not predicated from the bioinformatics analysis of the minicircle 
sequences in databases. To get around this problem and obtain clearer results (with only 
one band per sample), we built a second pair of primers targeting the conserved domain of 
the minicircle (Figure 15).  
Figure 15) Representation of k-DNA minicircle with primer position. A. k-DNA minicircle with 4 conserved 
domain shown as bold triangles, and 4 variable domains as thin lines. Primer position and amplicon formation 
have been represented as dashed lines. B. DeGrave’s minirepeat sequence demonstrating position and 
direction of primer sets 121-122 and Minicon-1-Minicon-2. 
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In Figure 16, results obtained with Minicon-1 and Minicon-2 primer set are 
presented. The primers produced the expected 113 bp band for the positive control. The 
predicted 113 bp band was also observed in the filtered urine samples, however two 
additional bands of ~120 bp and at ~300 bp were also observed. Each of the different sized 
bands (113 bp, 120 bp and 300 bp) were individually extracted and sent to sequencing. The 
resulting sequences were then identified as T. cruzi k-DNA using BLAST.  
Figure 16) 2% agarose gel of primers: Minicon 1- 2. Demonstrating 
different band sizes at 113 bp, 120 bp, 300 bp. L= 100 bp Ladder, W=water 
control, 1-4 = urine filtered samples, -C= negative control, +C= positive 
control (gDNA). 
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Study primer selection: Primers for the nPCR (TCZ 1-4) produced the correct expected 
band of 149 bp (Figure 13), while primers 121-122 amplified two bands of different sizes 
(Figure 14) and Minicon-1-2 amplified one band of the expected size and two bands of 
bigger size than expected (Figure 16). While these bands were of unanticipated sizes, they 
were all confirmed as positive for T. cruzi repeat sections after sequencing. For this reason, 
all three primer sets were selected for further studies. 
 Table 5 contains a summary of all primer sets used for the study, including 
sequence, target, predicted amplicon size, and references).  In the analysis of urine samples 
from the DC cohort outlined in the next section, we chose to test each urine sample with 
all three - 121-122, Minicon and nPCR - primer sets.  
 
 
  
 k-DNA Primers Target Amp. Ref. 
cP
C
R
 
121    
122 
5'-AAA TAA TGT ACG GGK GAG ATG CATGA-3' 
k-DNA 330 bp 
Shijman
70 5'-GGT TCG ATT GGG GTT GGT GTA ATA TA-3' 
M-1 
M-2 
5’-TTT GGG AGG GGC GTT CAA AT-3’ 
k-DNA 113 bp 
This 
article 5’-ACA CCA ACC CCA ATC GAA CC-3’ 
nP
C
R
 
TCZ1 5'-CCG ACG TCT TGC CCA CAC GGG TGCT-3' 
Sat-
DNA 
149 
bp 
Martins
82 
TCZ2 5'-CCT CCA AGC AGC GGA TAG TTC AGG-3' 
TCZ3 5'-TGC TGC AST CGG CTG ATC GTT TTC GA-3' 
TCZ4 5'-GAR GST TGT TTG GTG TCC AGT GTT GTGA-3' 
Table 5) Summary of study primers targeting T. cruzi, their amplicon and reference. cPCR= conventional 
PCR, nPCR= nested PCR, M-1=Minicon-1, M-2=Minicon-2, Amp. =Amplicon, Ref. =Reference. 
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DC Cohort Samples Analysis.  
Study participants. A total of 36 participants provided urine samples. Four individuals 
provided a second urine sample at a later time point, for a total of 40 urine samples. Of the 
36 volunteers, 9 (25%) were male, 25 (69.4%) were female, and 2 (5.5%) preferred to not 
answer this question.  While most of the participants (19; 52.8%) ranged between 40-59 
years old (with a mean of 42.1 ± SD 11.8), 30.6% were in the 18-39 age group.  The majority 
of the participants originated from El Salvador (18, 50%) or Bolivia (11, 30.6%). Summary 
of the demographics of the volunteers is presented in Table 6. 
 
Variable n % 
Sex     
Male 9 25 
Female 25 69.4 
NA 2 5.6 
Age     
18-39 11 30.6 
40-59 19 52.8 
≥ 60 3 8.3 
NA 3 8.3 
Location     
El Salvador 18 50 
Bolivia 11 30. 6 
Argentina 2 5.6 
Guatemala 2 5.6 
Costa Rica 1 2.8 
Peru 1 2.8 
NA 1 2.8 
     
 Table 6) Epidemiological variables in study population (n=36). 
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Electrophoresis Results. Figure 17 shows an example of the gel results using the same set 
of DNA templates for each of the three primer sets. Each PCR was run blindly to prevent 
bias. Following thermal cycling protocols outlined in the methods section, each gel was 
run with numbered filtered urine samples (1-10), a negative control (-C), a positive control 
(+C), and 100 bp ladder (L) for sizing [Results master table in the Appendix; Table 10]. 
From the three primer sets used, the nested PCR targeting Sat-DNA proved to be 
the most sensitive. Producing the predicted sized band of 149 bp in both the positive control 
(+C) and filtered urine samples (Figure 17-A).  
Minicon primers, targeting k-DNA, produced the correct sized band of 113 bp for 
some samples, and different sized bands (one at ~120 bp, and a third at ~300 bp) for other 
urine samples. It also produced the correct sized band for the positive control (+C) at 113 
bp (Figure 17-B).  
Primers 121-122, targeting k-DNA, produced the correct band size of 330 bp for 
the positive control (+C) but bands ~124 bp and/or ~270 bp from the clinical samples 
(Figure 17-C). Previous sample from the Argentina preliminary results was also used as 
comparison against the newly acquired samples and a difference in sensitivity was 
observed (results in Figure 25; Appendix). 
All bands, including each of the different sized bands, were individually extracted 
and sent for Sanger sequencing. All resulting sequences were then identified positively as 
T. cruzi k-DNA using BLAST.  Thus, despite generating PCR products different from the 
predicted size, based on the literature and informatics analysis, all of the PCR products, 
regardless of size, were verified as originating from T. cruzi minicircle Tr-DNA. 
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Figure 17) 2% agarose gel of 
primers: TCZ1-TCZ4 and 
Minicon-1-2:  
A. nPCR, 149 bp  
B. Minicon-1-2, 113 bp  
C. 121-122, 330bp.  
L= 100 bp Ladder, W=water 
control, A-E = urine filtered 
samples, -C= negative control, 
+C= positive control (gDNA). 
Each run was run blindly to 
prevent bias (sample numbers 
1-10 are random). 
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PCR Analysis of Tr-DNA from the DC Cohort. Of the 36 urine samples that were tested 
using nPCR, Minicon and 121-122 primer sets, 13 were positive for T. cruzi Tr-DNA with 
at least one of the primer pairs. Of the 36 samples, seven were positive with nPCR, nine 
with Minicon, and only one with 121-122 (Figure 18-A). The 121-122 primer data was 
excluded for further analyses since it only contained one positive sample.  The results from 
all of the samples can be found in Table 10 in the Appendix. 
 
In Figure 18-B, the concordance between the nPCR and Minicon primers is 
visually represented as a Venn diagram. We observed that three samples were concordantly 
positive for T. cruzi Tr-DNA with both the nPCR and Minicon primer sets, while 23 
samples were concordantly negative for all three primer sets (represented by the blue 
numbers in the diagram). A summary of the positive samples can be seen in Table 7. 
 
 
 
Figure 18) Venn Diagrams of nPCR, Minicon, and 121-122 A. summary of concordant positive samples 
distributing between nPCR, Minicon, and 121-122 in a series of 36 samples. B. Diagram summarizing 
concordant pairs between nPCR and Minicon, black color represents positive samples, and blue 
represents negative samples. 
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Only one sample (sample 229, 
Table 7) was positive for all three PCR 
primers. Between both nPCR and 
Minicon there were 13 PCR positive 
samples. Of this 13, only three were 
concordantly positive between both 
primers; six were positive with only 
Minicon, and four were positive with 
only nPCR. 
 
 
Four participants (207, 219, 229, 388) provided an additional urine sample on a 
subsequent visit to the clinic.  Each of these repeat samples (R) were analyzed and the 
results were compared to the results of the 
initial sample (I) (Table 8). The three 
participants who were negative for T. cruzi Tr-
DNA with all three primer sets at the initial 
visit were also negative at the second visit.  
However, the repeat sample provided by one 
participant (sample 229 whose initial sample 
was positive for all primer sets) was positive for the nPCR primers, inconclusive for the 
Minicon primers and negative for the 121-122 primers. 
 
Positive PCR 
Sample 
ID 
nPCR Minicon 
121-
122 
229 1 1 1 
359 1 1 0 
361 1 1 0 
218 1 0 0 
208 1 0 0 
358 1 0 0 
357 1 0 0 
327 0 1 0 
345 0 1 0 
216 0 1 0 
360 0 1 0 
380 0 1 0 
274 0 1 0 
Table 7) Table of positive sample results for nPCR, 
Minicon, and 121-122 (1=positive, 0=negative). 
 
Sample ID nPCR Minicon 121-122 
I 207 - - - 
R 207 - - - 
I 219 - - - 
R 219 - - - 
I 229 + + + 
R 229 + # - 
I 388 - - - 
R 388 - - - 
Table 8) Analysis of replicate samples from 
four patients using the nPCR, Minicon and 
121-122 primer sets. (# =inconclusive, + 
=positive, - =negative). 
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Serology. Of the 36 individuals who provided a sample, 34 were tested for T. cruzi antigens 
by serology.  Two patients declined to provide a serum sample. For the serological analysis, 
samples were considered positive when two of the four tests results were positive 
(following Gilman lab’s parameters). Of the 34 samples, 16 were designated to be 
serologically positive and 18 were negative. 
Table 9 summarizes the difference in results observed between the serological tests used.  
 
RT    
Positive 21    
Negative 12  
NA 1    
Hemagen 
2 tests = 
final 
positive 
  
Positive 17   
Negative 14   
Indeterminate 3   
Wiener Recombinant   
Positive 14 Serology Final 
Negative 20 16 Positive 
Wiener Lysate 18 Negative 
Positive 11   
Negative 10   
NA 13   
TESA-blot   
Positive 14   
Negative 16   
NA 4   
 
Table 9) Serology results summary in study population (n=34). RT= CDP whole blood Rapid Test. 
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PCR and Serology comparison.  Of the 34 samples analyzed for Tr-DNA using nPCR and 
Minicon primers and for anti-T. cruzi antibodies, only one sample was positive for both 
Tr-DNA and antibodies (Figure 19). Serology was positive for 16/34 samples. For the 
seven nPCR-positive samples, three were concordantly positive with serology, and of the 
eight Minicon- positive samples, two were concordantly positive with serology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 19) Venn Diagrams of PCR and Serology: summary of concordant pairs between nPCR, Minicon, and 
Serology final results. 
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Concentration Statistical Analysis. From the 40 urine samples collected, 38 were analyzed 
to test whether the volume of urine samples correlated with final concentration of DNA 
extracted. Two samples were omitted from this analysis as outliers from concentration and 
volume analysis, since their DNA concentrations were too high (80.8 and 71.1 ng/µL) due 
to menstruation/infection at time of collection Interestingly, this did not seem to affect PCR 
results from these samples. The average urine volume collected was 45 mL and the average 
concentration of DNA extracted from the filters was 2 ng/µL. No correlation was found 
between volume of urine filtered and DNA concentration extracted (p-value of 0.9253) 
(Figure 20). These results may be biased by amount of DNA a filter can capture and hold 
and the small number of samples. 
 
Figure 20) Correlation Scatterplot of volume vs concentration. 
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Discussion 
 
Chagas disease has been a public health concern for a long time in Latin America.  In 
recent years this concern has become more global with approximately 8 million people 
infected worldwide and at least 100 million at risk of infection1,31. However, this is likely 
an underestimate since these infections are difficult to detect and in non-endemic countries 
the index of underdiagnosis is estimated to be 95%5,57. This is due to a combination of 
asymptomatic cases, congenital infections, undocumented migrants with difficulty 
accessing care, and difficulty of diagnosis. Current diagnosis of Chagas disease is not 
straightforward, especially when it comes to the chronic phase of infection. Improving 
diagnosis to a direct method would help with faster and broader detection. In this study, 
we were able to detect T. cruzi DNA from patient’s urine samples utilizing Tr-DNA PCR 
tests, which could provide a more accurate and less invasive method of detection in the 
future.  
The validity of tests for Chagas disease depends on the phase of infection. In the acute 
phase (6-8 weeks) trypomastigotes are found in the blood (and, occasionally, other body 
fluids such as cerebrospinal fluid) and can be detected through direct microscopic 
visualization5. Following the acute phase, 30% of the patients transition into the chronic 
phase of infection, which can last 10-30 years5, where amastigotes are intracellular and 
parasitemia is low and intermittent, making diagnosis difficult. Chronic phase diagnosis is 
not straightforward due to the intracellular nature of the amastigote stage, and tests to detect 
this phase rely on patient’s history and clinical findings (previously diagnosed with acute 
infection, presentation with an enlarged heart with Chagas etiology, lived in Chagas 
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endemic country, mother previously diagnosed with Chagas) and indirect serological tests 
based on parasite-specific IgG antibody detection59. While there is no “golden standard” 
set up as reference, a confirmatory diagnosis requires two different serological tests, with 
a third test for confirmation when results are incongruous (that is after also including 
ECG’s, X-rays, endoscopy, and other tests to observe disease progression when infection 
is suspected57).  
All these tests require trained lab technicians and physicians in order to recognize and 
determine a confirmatory diagnosis. Additionally, serological tests have a highly variable 
sensitivity for samples obtained from different geographical regions63,4,64, further 
complicating diagnosis. Better diagnosis tests are also needed in order to monitor treatment 
efficacy (when testing new antitrypanosomal drugs) since both drugs currently available 
for treatment are not optimal and present many adverse effects76. With serological tests, 
monitoring is not possible since they cannot discriminate between an active infection or 
successful cure post-treatment 5, ,62. They can give false positive results due to antibody 
persistence after the parasite has been cleared from the body.  Serology can also provide 
false negative results.  Treatment with current drugs, which only attack extracellular 
trypomastigotes79,80, does not guaranty 100% parasite clearance and a patient with low 
level infection (intracellular amastigotes) may have anti-T. cruzi antibody titers too low to 
detect using the current tests.  
To circumvent the issues with serological detecting and to improve diagnosis, many cf-
DNA detection methods have arisen. Most focusing in PCR detection of T. cruzi from 
serum samples7–10,68. These PCR molecular techniques have proven to be highly specific 
and reproducible (targeting either sat-DNA or k-DNA), and are able to show positive 
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results days to weeks before trypomastigotes are visible by microscopy of peripheral 
blood49. However, so far, these methods are not sufficiently standardized to be used 
commercially and are only used in cases of inconclusive serological results 5,64,69,70. They 
also focus on detection of DNA in serum, which is most useful during the acute phase of 
infection. 
In order to be able to detect both acute and chronic infections, we have focused in 
detection of Tr-DNA from urine samples. Previous work performed in our lab has proven 
this method to be sufficiently specific and sensitive to be used as a diagnostic for other 
parasitic diseases such as Schistosoma haematobium73, Strongyloides stercoralis83, and 
Taenia solium84; being sufficiently sensitive to detect low and cryptic infections83. Not only 
that but the use of filtered paper to store DNA from urine samples proved to be cost 
effective, less time consuming, and facilitated specimen collection and transport. Other 
studies have also found cf-DNA in urine to be a useful biomarker for diagnosis of other 
parasitic diseases including malaria62,85–87, African sleeping sickness88, leishmania89,90, 
toxoplasma91. With this large range of parasites where cf-DNA has shown to be a useful 
diagnostic, detection of pathogen-specific DNA fragments in the host urine can be argued 
to provide direct evidence that the pathogen is present83. Urine cf-DNA could also be used 
for treatment efficacy studies since, unlike antibody levels that remain high long after drug-
mediated clearance of the pathogen, cell-free DNA is removed rapidly from the system as 
demonstrated by Ibironke et al. when examining schistosome infected cases two weeks 
post-treatment with praziquantel92. 
To determine whether T. cruzi Tr-DNA could be detected from patient’s urine samples, 
samples were collected/processed/and tested with three different conventional PCR 
 
57 
 
primers targeting T. cruzi specific repeat regions (sat-DNA and k-DNA) and compared 
against serological results. For this study, 36 volunteers (18-60 years old) from a Chagas 
Disease cohort study in the DC-Virginia area provided urine samples, with four providing 
extra specimens for a total of 40 samples. All of the urine samples were processed through 
filters, and DNA was extracted using a commercial DNA extraction kit. PCR analysis 
followed, with two reference primer sets (121-122 targeting the kinetoplast variable region, 
and TCZ-1-4 targeting the sat-DNA conserved repeat) and one in house primer set 
(Minicon1-2 targeting the kinetoplast conserved domain) – additionally each sample was 
analyzed by the Gilman group using four serological tests per sample. For the purpose of 
this study, the presence of T. cruzi-specific DNA in PCR results was considered indicative 
of infection only after sequencing confirmation; and a sample was considered serologically 
positive after two positive serological results. 
 Of the 36 samples, we identified 13 positive for infection with PCR and 16 with 
serology (Figure 19 and Table 10). PCR positive fragments were identified in specimens 
with both positive and negative serological results. Of the 16 serologically positive 
samples, 6 were positive for parasite-derived DNA. The remaining 10 samples with 
positive serology results were negative by PCR analysis despite repetition, which might be 
suggestive of false positive serology results due to presence of anti-T. cruzi antibodies after 
disease clearance.   Alternatively, it is possible that there was no observable DNA in the 
urine at time of collection or that T. cruzi DNA fragments other than the ones our primers 
amplified were present. Six samples were negative by serology and positive by PCR, which 
strongly suggests that the serology resulted in a high level of false negative findings. 
Presumably, while there are parasites present, there was not sufficient anti-parasite 
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antibody present in the blood when tested.  This could be due to chronic disease with low 
antibody titer, or due to the presence of anti-parasite antibodies that recognized epitopes 
not present in the antigen preparations used to construct the five antibody-detection tests 
used in this study.  
In the PCR gel electrophoresis results, it is also important to note that the positive 
controls used were T. cruzi genomic DNA, while sample DNA was Tr-DNA that most 
likely originated from dead and dying parasite cells, passive release, or active 
secretion62,72,93. While all 13 PCR positive samples were confirmed through sequencing, 
there were also differences in results observed depending on which PCR primer set used 
(See Table 5 for primers). Seven samples were positive with the nPCR primer set, nine 
with Minicon, and one with 121-122, not all of which were congruent with each other (See 
Figure 18 for PCR results). The nPCR, targeting sat-DNA TCZ minisatellite region, 
amplified the expected fragment of 149 bp for both samples and positive controls, as well 
as demonstrating brighter bands (higher sensitivity) than other primer sets used. This 
increase in sensitivity is attributed to the nested PCR protocol followed82, in contrast to the 
conventional PCR method used for the other primers. The Minicon primer set, targeting 
the kinetoplast conserved domain segment, demonstrated the expected band of 113 bp in 
the positive control and samples as well as two differently sized bands at ~120 bp and ~300 
bp in the samples. Similarly, primer set 121-122, targeting the k-DNA variable repeat 
domain, amplified the expected 330 bp fragment for the positive control, while amplifying 
120 bp and 270 bp bands in different samples. The differently sized bands were 
demonstrated to have originated from T. cruzi k-DNA after sequencing, with blast hits of 
95% identity to T. cruzi repeat segments.  
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The incongruent results between primer sets, as well as unexpected band sizes observed 
in samples, may be due to composition of the DNA (nuclear + kinetoplast) that is known 
to differ between DTU’s due to the different number of repeat fragments16 and/or variation 
in the sequence and size of the repeats. In addition, differences in band sizes between 
samples and positive controls may be due to processing and fragmentation of cf-DNA as it 
passes through the kidney to become Tr-DNA71,72.  
In order to gain insight into the origin of these unanticipated PCR products, we 
analyzed the sequencing results for each individual band.  While the bands confirmed as 
T. cruzi-DNA fragments, the resulting sequences were larger than the predicted size. This 
size differences were likely due to amplification artifacts that happened during 
amplification or template generation, were extra sequence was added to the core T. cruzi 
repeat sequence. While a larger sample size would be needed to determine how the 
different size fragments were generated, these results confirmed that all of the PCR 
products originated from T. cruzi repeat DNA. 
 We also observed that the concentration of DNA for each sample did not correlate 
with the total volume of urine filtered (p-value= 0.9567, Figure 20). This is important to 
note since samples are collected in the field and the volume of urine collected from patients 
cannot be controlled. These findings would need further analyses with a larger sample size 
since results may be biased by the amount of DNA a filter can hold, and by how much of 
the filter is in contact with the urine. DNA urine concentration has also been shown to vary 
depending on time of day collected, diet, changing pH levels, storage, and extraction 
methods used94–96. These measurements only represent the total DNA extracted from each 
sample, since a nanodrop does not differentiate between human and parasite DNA we 
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cannot know what portion of the 2 ng/µL is human and what portion is T. cruzi DNA. We 
also noted that frozen urine samples (at -80oC, for 1 year) were not optimal for PCR DNA 
analysis, since all DNA seemed to have degraded. While a bigger sample pool would be 
needed in order to be confirmed (for filtered urine method) our results agree with Soto et 
al.’s results97, where they found that long-term frozen urine samples are not optimal for 
DNA extraction and use as template in PCR detection, regardless of extraction methods 
used. 
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V. Conclusion and Future Work 
 In this study we were able to demonstrate that T. cruzi DNA can indeed be detected from 
human filtered urine samples. While future work is still needed, these findings present the 
possibility for a non-invasive Chagas disease diagnostic test, with the possibility of accurately 
detecting both acute and chronic phases of the disease. In addition, this test could be used for early 
detection of congenital disease, disease re-emergence, and the monitoring of treatment efficacy. 
Future Directions. T. cruzi Tr-DNA detection may be a more direct and specific measure of both 
the acute and chronic phases of Chagas disease. However, a larger number of samples would be 
needed in order to obtain its sensitivity when compared with current diagnostic methods. Primers 
may also need to be improved in order to recognize different DTU’s and other repeat fragments 
found in urine samples not amplified with the primers used in this study. For this to be possible, 
Next Generation sequencing could be used to survey all of the parasite-derived DNA that is present 
in the urine from infected individuals. Sequencing urine samples through this method could identify 
additional T. cruzi repeat fragments present in the urine.  This would lead to better primer design 
and the development of a multiplex-PCR system could provide a more sensitive and less variable 
method of diagnosis.  
In order to improve current Chagas disease diagnosis, and decrease under diagnosis levels 
in non-endemic countries, I believe a new plan of action is needed. A compromise between serology 
and PCR analysis (one serology test and one PCR test, instead of two serological tests with a third 
as confirmation), in a point of care system, could be made in order to give faster confirmatory 
diagnostics. Furthermore, if an alternate parasite-detection method could be obtained from filtered 
urine samples, (for example detect both parasite antigens and Tr-DNA), this would further facilitate 
precision in the diagnosis of T. cruzi infections in humans. 
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Appendix 
Supplementary Results - Sequencing 
 
Sequencing + Bioinformatics. Bands were individually extracted and sent to Macrogen 
for sequencing, including differently sized bands found in samples. However, the resulting 
sequences obtained after sequencing did not agree with the size band that had been 
extracted from the gel (e.g. a band sized 149 bp would be extracted and sequencing results 
would return a 200-1300 bp fasta sequence) due to restrictions in sequencing parameters. 
In order to verify both the presence of DNA and confirm band size after extraction, all 
sample bands were then also run through a tape station. The results for the nPCR samples 
can be seen in Figure 21. The aggregated peaks at 149 bp represent the resulting band size, 
confirming that the bands extracted and sent for sequencing were this size.  This process 
was followed for each positive sample band, for all sets of primers. 
Figure 21) Tape station results. X=band size (bp), Y=Sample Identity. Each sample is individually 
indicated by a different color. Sample A8 is a pool of all samples, and H7 is the genomic positive control. 
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All presumptive positive samples were also confirmed as T. cruzi positive through 
BLAST after sequencing and tape station size confirmation. Figure 22 demonstrates the 
Blast results for one sample. As mentioned above, results from sequencing were longer 
than expected for each sample (in this case a positive sample band from nPCR of 149 bp 
was sent and a 700 bp sequence was returned, even after being confirmed to be 149 bp by 
tape station analysis). 
Figure 22) NCBI BLAST results. In blue is the query sample sequence, and smaller pink lines all represent 
hits to T. cruzi Sat-DNA. On the right are results for the first three hits. 
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These results not only re-confirmed the expected band sizes, they also allowed for 
query sample sequences to be cleaned, and a sample library was formed for each primer 
set. As well as confirming that the bands observed were T. cruzi positive (including 
differently sized bands observed with primer sets Minicon 1-2 and 121-122). These 
sample results were also compared against the sequence obtained from the positive 
control for further confirmation (Figure 23). 
 
Through these analyses we were able to also observe the repetitive nature of this 
small DNA fragments (Figure 24). While not all hits were repeats, and there was much 
variability between results, all sample bands run for the different primer sets were 
confirmed to be part of tandem repeats. While further analysis and more samples would be 
needed to demonstrate that the differently sized bands are fragments from these tandem 
repeats, these results are presumptive evidence. 
  
Figure 23) Sample alignment against positive control. ClustalX results demonstrating alignment with 
asterisk (*) representing amino acid placement conserved through all sequences. Positive control is 
signaled by the red square. 
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Figure 24) NCBI BLAST repeat results. Positive sample sequence was used as query sequence. It is 
observed to be repeated 12 times with different hits to a T. cruzi hypothetical gene. 
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A. IRB Approval 
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B. Argentina preliminary sample (F) vs. DC samples with primer 
121-122. 
 
  
Figure 25) DC samples vs Argentina sample. 2% agarose gel of primers 121-122 
(330bp) L= 100 bp Ladder, W=water control, D-E = urine filtered samples, -C= 
negative control, +C= positive. 
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C. Results Master Table. 
 
 
 
Table 10) Results master table. In the first column are the sample identification numbers (ID), highlighted 
in in blue are the repeated samples. Second column is urine volume of specimen in mL and third column is 
DNA concentration extracted in ng/µL. Fourth to sixth column are PCR results, and Seventh to twelfth 
column are serology results;  positive results are represented by a “1” and highlighted in yellow, negative 
results are represented by a “0”, inconclusive results are represented by a “2”, and NA represents no sample 
available. In the thirteenth column “F” =Female and is highlighted in pink, “M” =Male and is highlighted in 
blue. The fourteenth column shows patient origin with different geographical areas represented by different 
numbers and text color. Finally, the fifteenth column shows the patient’s age. In the three last columns “NA” 
=no answer. 
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● Maintained Lab Notebook Guide, organized microscope slides for lab 
sections, communicated with students, held office hours, and graded 
assignments. 1 term (Dr. Clive J. Shiff & Dr. David A. Sullivan) 
 
Leadership Experience 
2013 - 2014  Vice President of Hip Hop Movement, University of California Merced 
[HHM is a nonprofit organization that combines the four branches of Hip Hop: 
DJ, Graffiti, Spoken Word, and Dance. It strives to bring together the 
community and  
the student population to teach the culture of Hip Hop] 
● Managed paperwork for on and off-campus events 
● Networked with several organizations  
● Coordinated a series of events with other team members, organizing 
competitions and headliner 
● Participated in student assembly discussions 
● Assisted in the initial development of the first Black Arts Movement 
Conference held at UCM 
● Managed what totals to $10,500 in events and raised funds for the 
club 
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Skills and Additional Training 
Professional Training 
Expected 2019  Certificate in Tropical Medicine, Johns Hopkins Bloomberg School of Public  
Health, Baltimore, MD 
 
Oct 2017  Biosafety: Bloodborne Pathogens Training, Skaggs School of  
Pharmacy and Pharmaceutical Sciences, University of California San Diego 
 
Feb 2016  Annual Laboratory Hazards Training, Section of Molecular Biology,  
University of California San Diego 
 
Feb 2016  UC Laboratory Safety Fundamentals, Section of Molecular Biology,  
University of California San Diego 
 
2015-2016  Certificate in CPR/AED, University of California Merced 
 
Software 
● Proficient with Excel, Word, PowerPoint and other Microsoft Office Software 
● GraphPad Prism 
● Bioinformatic tools: BioV Suite, Fig Tree, MEME 
● Alpha View 
● PSI-BLAST, Primer-BLAST (NCBI) 
 
Programming 
● Basic scripting knowledge in R, BASH Shell, Linux, Python, C, and C++ 
 
Technical Skills 
● FluorChem imagers 
● High Throughput analysis 
● PCR  
● ELISA 
● Cell Culturing 
● DNA Extractions 
● Electrophoresis 
● Sequence Analysis 
 
Languages 
● Fluent in English and Spanish 
